#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Advanced systemic mastocytosis Leber's congenital amaurosis Metastatic gastric cancer Cutaneous calcification Frostbite Non-renal cell carcinoma of kidney Immunodeficiency Antithrombin III deficiency Chronic granulomatous disease Arginase deficiency Pyruvate kinase deficiency anaemia Orthostatic hypotension Desmoid tumour Noonan syndrome Mixed-type liposarcoma More trials…

    Learn about Rare Diseases

    Mitochondrial myopathy Encephalitis autoimmune – Trials in Disease Osteosarcoma – Basic Information Hepatoblastoma – Treatment Glycogen storage disease type II – Diagnostics Carcinoid syndrome – Life with Disease Antisynthetase syndrome – Trials in Disease Congenital nephrogenic diabetes insipidus – Trials in Disease Burkitt’s lymphoma – Treatment Familial amyotrophic lateral sclerosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Odm-208 Lanifibranor Ivabradine Bi 765845 89ZR-CED88004S Camlipixant Fluoxetine L-Ascorbic Acid Ucp2 Mps-106 ALN-961583 Trastuzumab Emtansine Gozetotide Alf-18 Brexpiprazole Syn2 Vixarelimab Molidustat Sodium Clindamycin Phosphate Ict01 Linagliptin More therapies…

    Learn about Your Condition

    Bipolar I disorder Haemorrhagic stroke Polymyalgia rheumatica Leukaemia Haematological infection Delirium Turner's syndrome Psoriatic arthropathy Neuromuscular scoliosis Pleural mesothelioma Dementia Alzheimer's type Relapsing multiple sclerosis Septic shock Drug dependence Advanced systemic mastocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study on the Effect of Famotidine in Reducing P-selectin Levels in Children with Sickle Cell Disease

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Famotidine
    France

  • Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine
    • Olaparib
    France Germany Hungary Ireland Poland Spain

  • Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    Denmark France Ireland Italy Romania Spain

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Letermovir
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma recurrent
    • Diffuse large B-cell lymphoma refractory
    Investigated Drugs:
    • Allo-501A
    • Allo-647
    • Letermovir
    Austria Belgium Germany

  • Study on Ganaxolone for Patients with Refractory Status Epilepticus

    Not recruiting

    3 1
    Investigated Diseases:
    • Status epilepticus
    Investigated Drugs:
    • Ganaxolone
    Austria Belgium Croatia Czechia Denmark Finland +8
Previous Page
1 … 1,692 1,693 1,694 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!